HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Ovid Therapeutics (NASDAQ:OVID) and maintained a price target of $9.
May 16, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Ovid Therapeutics and maintained a price target of $9, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $9 price target by HC Wainwright & Co. suggests strong confidence in Ovid Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100